Every year, a significant number of individuals across the globe contract the influenza virus, leading to the manifestation of severe symptoms and, in some cases, fatal outcomes, thereby posing a grave threat to human well-being. Vaccination prevents infections and reduces influenza-related mortality. Given the limitations associated with current influenza vaccines, such as their reliance on fertilized chicken eggs, limited production capacity, the need for egg adaptation, and prolonged production time, exploring alternative methods is a must. In light of these drawbacks, cell-based manufacturing presents itself as a viable alternative for the production of influenza vaccines. The history of cell-based influenza vaccine development Over the past 80 years, various methods have been developed to culture influenza viruses. In 1933, the first human influenza virus was isolated by propagating specimens obtained from throat washings collected from a patient, using ferrets thr